Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 12/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL638750 | 1.00 | SLC29A1 (1.00) | SLC29A1TP53ADORA3TDP1 | |
| SCHEMBL20626431 | 1.00 | SLC29A1 (1.00) | SLC29A1TP53ADORA3TDP1 | |
| SCHEMBL14713263 | 1.00 | SLC29A1 (1.00) | SLC29A1TP53ADORA3TDP1 | |
| SCHEMBL3895881 | 1.00 | SLC29A1 (1.00) | SLC29A1TP53ADORA3TDP1 | |
| SCHEMBL638628 | 0.91 | SLC29A1 (0.84) | SLC29A1TP53ADORA3TDP1 | |
| SCHEMBL638629 | 0.91 | SLC29A1 (0.84) | SLC29A1TP53ADORA3TDP1 | |
| SCHEMBL640539 | 0.90 | SLC29A1 (0.81) | SLC29A1TP53ADORA3TDP1 | |
| SCHEMBL640540 | 0.90 | SLC29A1 (0.81) | SLC29A1TP53ADORA3TDP1 | |
| SCHEMBL8572281 | 0.89 | SLC29A1 (0.80) | SLC29A1ADORA3 | |
| SCHEMBL8572278 | 0.89 | SLC29A1 (0.80) | SLC29A1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060166925-A1 | Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2006-07-27 | — | — | US | claimed |
| EP-1575973-A2 | SUBSTITUTION DERIVATIVES OF N SP 6 SP -BENZYLADENOSINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) | 2005-09-21 | — | — | EP | claimed |
| WO-2004058791-A2 | SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2004-07-15 | — | — | WO | claimed |
| CN-102812033-A | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | INST MATERIA MEDICA CAMS | 2012-12-05 | — | — | CN | disclosed |
| US-8119614-B2 | Substitution derivatives of N6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2012-02-21 | — | — | US | disclosed |
| US-7582616-B2 | Nucleoside transport inhibitors | QUESREMA ENTERPRISES LLC (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070293444-A1 | Novel Nucleoside Transport Inhibitors | BUOLAMWINI JOHN K | 2007-12-20 | — | — | US | disclosed |
| US-20060166925-A1 | Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2006-07-27 | — | — | US | disclosed |
| EP-1575973-A2 | SUBSTITUTION DERIVATIVES OF N SP 6 SP -BENZYLADENOSINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004060902-A2 | NOVEL NUCLEOSIDE TRANSPORT INHIBITORS | BUOLAMWINI JOHN K (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004058791-A2 | SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166925-A1 | Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | ADAR, ADORA2A, AMPD2 | SLC29A1 399/4885TP53 112/4885ADORA3 14/4885 |
| US-20070293444-A1 | Novel Nucleoside Transport Inhibitors | SLC29A1, SLC29A2, SLC28A1 | SLC29A1 1/4885TP53 1256/4885ADORA3 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.